ongoing

In patients receiving a factor Xa inhibitor who are experiencing an acute major bleed, the objectives of this study are to demonstrate the decrease in anti-fXa activity and to evaluate hemostatic efficacy following andexanet treatment.

Study Type

Interventional - Drug

Study Design

Multicenter, prospective, open-label study

NO. of Countries

9

NO. of Sites

81

NO. of Participants

466

Study Period

2015-2020

Sponsor

Portola Pharmaceuticals

Back To Top